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OBJECTIVES: Previous studies have reported that osteoporosis due to estrogen deficiency influences fracture
healing. Transforming growth factor (TGF-b) has been found to be involved in fracture healing via the regulation of
the differentiation and activation of osteoblasts and osteoclasts. The current study aimed to determine the effects
of estrogen on the expression of TGF-b1 during fracture healing in ovariectomized rats.
METHODS: Thirty female Sprague-Dawley rats weighing 200–250 g were assigned to: (i) a sham-operated group
that was given a normal saline; (ii) an ovariectomized control group that was given a normal saline; or (iii) an
ovariectomized + estrogen (100 mg/kg/day) group that was treated with conjugated equine estrogen. The right
femur of all rats was fractured, and a Kirschner wire was inserted six weeks post-ovariectomy. Treatment with
estrogen was given for another six weeks post-fracture. At the end of the study, blood samples were taken, and the
right femur was harvested and subjected to biomechanical strength testing.
RESULTS: The percentage change in the plasma TGF-b1 level before treatment was significantly lower in the
ovariectomized control and estrogen groups when compared with the sham group (p,0.001). After six weeks of
treatment, the percentage change in the plasma TGF-b1 level in the estrogen group was significantly higher
compared with the level in the ovariectomized control group (p=0.001). The mean ultimate force was significantly
increased in the ovariectomized rats treated with estrogen when compared with the ovariectomized control group
(p=0.02).
CONCLUSION: These data suggest that treatment with conjugated equine estrogen enhanced the strength of the
healed bone in estrogen-deficient rats by most likely inducing the expression of TGF-b1.
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INTRODUCTION
Osteoporotic fracture is of great clinical importance as it
carries a high risk of morbidity and mortality.1 Osteoporosis
is a metabolic bone disease that results in decreased bone
mass and an increased risk of fracture.2 Postmenopausal
osteoporosis is considered the most frequent cause of
pathological fracture. Albright (1947) was the first to report
the primary role of estrogen deficiency in the pathogenesis
of postmenopausal osteoporosis.3 Bone is the only tissue in
the body that can regenerate without leaving a scar after
injury.4 Various local growth factors including bone
morphogenetic proteins (BMPs), insulin-like growth factor
(I-LGF), transforming growth factor-beta (TGF-b), platelet
derived growth factor (PDGF), and fibroblast growth factor
(FGF), which are all secreted by osteoblasts, and blood cells
have been reported to have a role in maintaining bone
metabolism and improving fracture healing by regulating
the differentiation of bone cells.5
The TGF-b superfamily is a group of cytokines that
includes TGF-b, activins, BMPs, and GDFs that regulate
the growth and differentiation of osteoblasts.6 TGF-b is an
extracellular protein that is produced mainly by osteo-
blasts and platelets.7 There are three isoforms of TGF-b
found in mammals: TGF-b1, TGF-b2, and TGF-b3. These
cytokines are involved in the regulation of cell prolifera-
tion and differentiation and in the suppression of the
immune system.8 Serum TGF-b has been correlated with
the platelet count as most TGF-b is produced by platelets.
Therefore, the TGF-b level is commonly measured in the
plasma.8 Several studies have investigated the role of
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TGF-b in promoting bone healing. It has been reported
that the topical application of estrogen improved the
incisional wound healing associated with increased
expression of TGF-b1 in ovariectomized rats when com-
pared with untreated ovariectomized rats.9 Furthermore,
it has been found that TGF-b is expressed at high levels in
healing fracture calluses.10 Cigarette smoking has been
reported to reduce the level of TGF-b1 after surgery,
which may delay healing.11 Another study reported that
decreased expression of TGF-b1 by osteoblasts may have
negative effects on fracture healing in ovariectomized
rats.12 Zinc supplementation has been reported to induce
the expression of TGF-b in vitro, and therefore, TGF-b1 is
essential for the healing process.13 Altogether, these
studies suggest that TGF-b may have a role in enhancing
bone fracture healing.
Bone loss following post-menopausal estrogen loss can be
reversed by estrogen replacement therapy. Hormonal
replacement therapy has been used since in the 1930s to
manage post-menopausal symptoms.14 It has also been
shown to protect against the development of osteoporosis,
coronary heart disease, and colorectal carcinoma.15 It has
been shown that estrogen replacement therapy (ERT)
prevents bone resorption, resulting in the maintenance of
skeletal mass and a reduced risk of fracture.16 Despite the
beneficial effects of ERT in reducing the risk of fracture, it
has been reported that the long-term, unopposed use of
estrogen therapy after menopause can increase the risk of
endometrial carcinoma and that this risk is reduced when
estrogen is combined with progesterone.15,17 However,
there have been few reports examining the level of TGF-b1
in the blood during estrogen replacement therapy. The
current study aimed to determine the effects of the
administration of conjugated equine estrogen on the level




Thirty female Sprague-Dawley rats weighing 200–250 g
were purchased from the Laboratory Animal Resource Unit,
Universiti Kebangsaan Malaysia (UKM). The rats were
housed individually in clean cages at room temperature
with a normal 12-hour light-dark cycle and free access to
water and food. The rats were acclimatized for two weeks
before they were randomly assigned to the sham-operated
(SX, n = 10) or ovariectomized (n = 20) groups. Following a
previously described protocol, the rats in the SX group
underwent a sham operation, whereas the rats in the
ovariectomized group underwent a bilateral ovariectomy
at the beginning of the study.18 This study was approved by
the Animal Ethics Committee of Universiti Kebangsaan
Malaysia (UKM).
Experimental Protocol
Osteoporosis was allowed to develop in the animals for
six weeks after the ovariectomy. A pilot study was carried
out prior to the main study to confirm the induction of
osteoporosis based on the bone-structural histomorpho-
metry.19 Following a previously described protocol,
the right femur of all rats underwent a closed fracture
at mid-diaphysis six weeks post-ovariectomy.20 Xylazil
and ketamine were given in combination as anesthetic
agents (Troy Laboratories, Australia) (1:1) at a dose of
0.1 ml/100 g I.M. to all of the rats prior to the fracture
procedure. To approach the anterior intercondylar notch,
a transverse incision was made on the right knee, and the
patella was displaced laterally. A Kirschner wire (K-wire,
1.0 mm) (Jorgensen Lab, USA) was inserted into the
anterior intercondylar notch toward the femoral medul-
lary canal as a fixator. Following internal fixation with the
K-wire, a guillotine-like blade device weighing 0.5 kg was
dropped from 30 cm of height to fall on the middle of the
right femur to generate standardized closed fracture with
minimal soft tissues trauma.
X-ray images were immediately obtained post-fracture to
confirm both the intramedullary placement of the K-wire
and the fracture. To prevent infection, 5% Enrofloxacin was
given at a dose of 10 mg/kg I.M. (Bayer, Thailand) daily
for 10 days with the daily dressing. On the first day post-
fracture, the sham (SX, n = 10) group was given a normal
saline vehicle, while the ovariectomized rats were further
subdivided into two groups: (i) the ovariectomized control
(VC, n = 10) group was given a normal saline vehicle; (ii)
the ovariectomized + estrogen (CEE, n = 10) group was
treated with conjugated equine estrogen (conjugated
estrogen, Premarin-Wyeth, Canada) at a dose of 100 mg/
kg/day. The estrogen dose used in this study was adopted
from earlier studies.20 Animals were weighed every three
days to adjust the given dose. Treatment was given daily
for six weeks via oral gavage immediately after fracture of
the right femur. At the end of the experiment, blood
samples were taken from the retro-orbital sinus of the rats
just before euthanasia. After euthanasia, the right femur
was dissected, and the K-wires were removed. All bone
samples were kept at -70 C˚ until use for biomechanical
testing. In addition, the uterus was removed from each rat
and weighed.
Biochemical Analysis (TGF-b1)
Blood samples were collected three times: at the
beginning of the study (before ovariectomy), before the
closed fracture (before treatment), and just before sacri-
fice. All blood samples were taken from the retro-orbital
sinus of the rats while they were under anesthesia with
diethyl ether. All of the samples were kept in an ice box to
prevent clotting. The blood was centrifuged at 4 C˚ and
4,000 rpm for 10 minutes to obtain plasma. Plasma
samples were placed in Eppendorf tubes and stored at
-70 C˚. The plasma TGF-b1 level was measured using an
enzyme-linked immunosorbent assay (ELISA), as recom-
mended by the manufacturer (TGF-b1 EIA Kit; Assay
designs, USA). An ELISA plate reader (Versamax,
Sunnyvale, USA) was calibrated against a blank substrate,
and the microplate was read at 450 nm. The average net
OD was calculated for each standard and sample by
subtracting the average blank OD from the average OD for
each standard and sample. All sample values that were
obtained using the TiterZyme TGF-b1 kit were converted
to the NIBSC/WHO TGF-b1 Standard using the following
equation:
NIBSC/WHO 87514 value (pg/ml) = Obtained human
TGF-b1 value (pg/ml)60.915
Biomechanical strength testing
Following a previously described protocol, the frozen
bone samples were thawed slowly at room temperature
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overnight.21 On the following day, the bone samples were
then analyzed using an Instron Microtester 5848 (Instron,
USA) to measure the ultimate force. A load was applied to
the middle of the femur diaphysis corresponding to the
fracture callus area until the bone was fractured. The
ultimate force was then calculated using the Bluhill software
package.
Statistical Analysis
Statistical analyses were carried out using SPSS Version
17. The baseline TGF-b1 data were not homogenous, and the
homogeneity of the variance (Levene’s test) was significant
(p,0.05). Because the assumption of the homogeneity of
variance was violated, the percentage difference of the TGF-
b1 levels was compared instead of the TGF-b1 levels alone.
Variables were analyzed using a 2-way mixed repeated
measure ANOVA with a post-hoc Tukey’s test. The results
are presented as the mean¡SEM. The level of significance
was set at p,0.05.
RESULTS
Uterine weight
Following six weeks of treatment, marked uterine atrophy
was observed in the VC group when compared with the SX
group (p,0.05). The uterine weight of the rats treated with
ERT was unchanged when compared with the SX group.
Finally, the uterine weight in the CEE group was consider-
ably increased following treatment with ERT when com-
pared with the VC group (p,0.05; Figure 1).
Biochemical Analysis (TGF-b1)
Biochemical testing was carried out to determine the
plasma level of TGF-b1. Blood samples were collected from
the rats at baseline (time zero), before treatment and after
treatment. The percentage change in the TGF-b1 level before
and after treatment with CEE were calculated as follows:
Percentage change before treatment = [TGF-b1 before
treatment – baseline] / baseline.
Percentage change after treatment = [TGF-b1 after
treatment – baseline] / baseline.
Before treatment, the percentage change in the TGF-b1
level was significantly lower in the CEE and VC groups
compared with the SX group (p,0.001). In the VC group, the
percentage change in the TGF-b1 level after treatment was
significantly lower when compared with the percentage
change before treatment (p,0.045). The percentage change
in the TGF-b1 level after treatment was significantly higher
in the CEE group when compared with the VC group
(p= 0.001), and it was identical in the CCE and SX groups
(p.0.05; Figure 2).
The percentage change in the plasma levels of TGF-b1 is
summarized in Table 1.
Biomechanical strength testing
Biomechanical analyses were performed to evaluate the
strength of the healed femur following six weeks of
treatment. The mean ultimate force (N) of the CEE group
was significantly greater than that of the VC group (p = 0.02),
and there was no significant difference between the CEE
and SX groups (p.0.05) (Figure 3).
Figure 1 - Mean uterine weights after six weeks of treatment. SX, sham-operated group given normal saline; VC, ovariectomized
control group given normal saline; CEE, ovariectomized group treated with conjugated equine estrogen at a dose of 100 mg/kg/day;
n =10. * Significant difference compared with the SX group (p,0.05). # Significant difference compared with the VC group (p,0.05).
The values are expressed as the mean¡SEM.
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DISCUSSION
The uterine weight was significantly decreased in the VC
when compared with the SX group. Additionally, ovar-
iectomy resulted in marked uterine atrophy in the ovar-
iectomized rats when compared with the SX group,
indicating the success of the ovariectomy procedure. The
same pattern has been reported in a previous study
performed by Fazliana et al., who concluded that the
ovariectomy-induced estrogen deficiency resulted in
marked uterine atrophy in rats.22 The uterine weight in
the CEE group was significantly greater than that of the VC
group. Although the ovariectomized rats treated with ERT
had a significantly increased uterine weight, the increased
uterine weight in the CEE group was still lower than that of
SX group. Zhang et al. also demonstrated that the uterine
weight is markedly increased in ovariectomized rats treated
with estrogen when compared with non-estrogen-treated,
ovariectomized rats.23 The treatment with CEE was able to
increase the uterine weight of ovariectomized rats, suggest-
ing that the dose of the estrogen therapy used in the current
study was adequate.
Several studies have shown that ERT prevents bone
resorption, resulting in the maintenance of skeletal mass
and a reduction in the risk of fracture.24 The relationship
between estrogen and the TGF-b is complex and not
completely understood. It has been shown that treatment
with estrogen prevents excessive bone loss via the TGF-b-
mediated promotion of osteoclast apoptosis.25 Furthermore,
Atti et al. reported that TGF-b has a role in the regulation of
bone homeostasis as it regulates osteoblast and osteoclast
activity.26 Previous studies have found that the local
application of TGF-b around the fracture site enhanced
fracture healing.27,28
Figure 2 - The percentage change differences in the plasma TGF-b1 level. SX, sham-operated group given normal saline for six weeks;
VC, ovariectomized control group given normal saline for six weeks; CEE, ovariectomized group treated with conjugated equine
estrogen (100 mg/kg/day) for six weeks; n=10. * Significant difference when compared with the sham group (p,0.001). # Significant
difference when compared with the BT-BL within the same group (p=0.045). a Significant difference when compared with the VC
group (p=0.001).
Table 1 - The percentage change in the plasma TGF-b1
level.
Group BT-BL (%) AT-BL (%)
SX 11.7¡5.64 -0.75¡11.08 a
VC -46.7¡3.68* -67.4¡4.53*,#
CEE -34.8¡5.92* -18.7¡8.08 a
BT-BL, percentage change before treatment; AT-BL, percentage change
after treatment. SX, sham-operated (vehicle normal saline, six weeks); VC,
ovariectomized control (normal saline, six weeks); CEE, ovariectomized +
estrogen (conjugated equine estrogen 100 mg/kg/day, six weeks); n = 10.
#Significant difference when compared with the BT-BL within the same
group (p=0.045).
*Significant difference when compared with the sham group (p,0.001).
aSignificant difference when compared with the AT-BL of the VC group
(p=0.001).
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The plasma TGF-b1 level prior to treatment was sig-
nificantly decreased in the VC and CEE groups when
compared with the SX group. Six weeks after ovariectomy,
all of the ovariectomized groups showed a significant
decrease in the plasma TGF-b1 level when compared with
the SX group. Estrogen deficiency resulted in a significant
decrease in the expression of TGF-b1 in ovariectomized rats.
A similar decreased expression of TGF-b1 in ovariectomized
rats (when compared with un- ovariectomized controls) has
been reported in other studies.29 This pattern suggests that
estrogen deficiency suppresses the expression of TGF-b1,
which may interfere with fracture healing.
Following treatment, the percentage change in the TGF-b1
level was significantly lower in the VC group compared
with the SX group at the same time point. It was also
significantly lower than the mean level before treatment
within the same group. Estrogen deficiency has been shown
to induce the production of various cytokines and decrease
the expression of TGF-b1, thereby inducing osteoclastogen-
esis.30 Previous studies have demonstrated that estrogen
loss results in decreased expression of TGF-b in osteoblasts
in ovariectomized rats when compared with the control
group.12,29,31 Furthermore, it has been reported that the
concentration of TGF-b1 in the blood is lower in patients
with delayed fracture healing.32 Therefore, the level of TGF-
b1 in the blood may be a marker for fracture healing.
The percentage change in the TGF-b1 level after treatment
was significantly higher in the CEE group when compared
with the VC group. Therefore, rats treated with estrogen
had a higher concentration of TGF-b1 in the blood when
compared with the VC group. Treatment with estrogen
likely improved osteoporotic fracture healing in ovariecto-
mized rats by inducing the expression of TGF-b1 in
osteoblasts.33 Liu et al. found that the TGF-b level in the
sham and ovariectomized + ERT groups was greater than
the level in the ovariectomized control group.29 In addition,
Hughes et al. found that estrogen prevented bone loss
through the TGF-b1-mediated induction of osteoclast
apoptosis.25 Altogether, this suggests that TGF-b1 may play
a role in fracture healing by preventing osteoporotic
changes and inducing callus formation.
The TGF-b1 level in the CEE group after six weeks of
treatment was not significantly different than the level
before treatment. It was also not significantly different when
compared with the SX group at the same time point. The
TGF-b1 level was increased six weeks post-ovariectomy,
and it was nearly identical to the normal concentration of
TGF-b1 in the SX group. This suggests that the administra-
tion of estrogen enhanced fracture healing in ovariecto-
mized rats by increasing TGF-b1 expression.
The restoration of the biomechanical strength of fractured
bones in patients is of great clinical importance.34 Therefore,
the biomechanical strength of the fractured femurs was
measured to evaluate fracture healing in estrogen-deficient
rats. Ultimate force is the most widely used biomechanical
parameter for measuring bone strength, and it represents
the ultimate compressive force applied to a bone until a
fracture occurs.35 There was a significant decrease in the
mean ultimate force in ovariectomized rats treated with
normal saline when compared with the SX group. Estrogen
Figure 3 - The mean ultimate force (strength) of the fractured right femur after 6 weeks of treatment. SX, sham-operated group treated
with normal saline for six weeks; VC, ovariectomized control group treated with normal saline for six weeks; CEE, ovariectomized +
estrogen group treated with 100 mg/kg/day of conjugated equine estrogen for six weeks; n =10. # p,0.05 compared with the VC
group. The values are expressed as the mean¡SEM.
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loss following ovariectomy resulted in a delay in fracture
healing, which led to the incomplete restoration of the
biomechanical strength of the fractured femurs. Previous
studies have found that the biomechanical strength of
fractured femurs in non-treated ovariectomized rats was not
restored when compared with normal control rats.21,36,37
There was a significant increase in the ultimate force in
the CEE group when compared with the VC group.
However, the ultimate force was identical in the CEE and
SX groups. Treatment with estrogen enhanced fracture
healing by restoring the biomechanical strength of healed
femur. This is in line with Cao et al., who reported that the
strength of the fractured bone in ovariectomized rats treated
with estradiol was identical to that in normal control
animals.38 Estrogen replacement therapy has been shown
to be beneficial in preventing bone loss and decreasing
fracture risk.16 Estrogen likely prevents bone loss or
excessive resorption of bone by suppressing the differentia-
tion and activity of osteoclasts.30 These data suggest that the
restoration of the biomechanical strength of the healed
femurs following treatment with estrogen may be attributed
to the increased expression of TGF-b1.
The current study demonstrated that estrogen deficiency
results in a significant decrease in the expression of TGF-b1
in the blood six weeks post-ovariectomy. Treatment with
estrogen induced the expression of TGF-b1 in the blood of
estrogen-deficient rats. Therefore, estrogen treatment may
have contributed to the restoration of bone strength in the
healed bone by increasing the expression of TGF-b1 in the
blood. Further studies are required to understand the role of
TGF-b in the regulation and differentiation of bone cells.
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